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Consensus Statement

An Expert Consensus Statement on the
Management of Large Chondral and
Osteochondral Defects in the
Patellofemoral Joint
Jorge Chahla,* MD, PhD, Betina B. Hinckel, MD, PhD, Adam B. Yanke, MD, PhD, Jack Farr, MD,
and Metrics of Osteochondral Allografts (MOCA) Group
Investigation performed at Midwest Orthopaedics at Rush and the Rush University Medical Center,
Chicago, Illinois, USA
Background: Cartilage lesions of the patellofemoral joint constitute a frequent abnormality. Patellofemoral conditions are challenging to treat because of complex biomechanics and morphology.
Purpose: To develop a consensus statement on the functional anatomy, indications, donor graft considerations, surgical treatment, and rehabilitation for the management of large chondral and osteochondral defects in the patellofemoral joint using a
modified Delphi technique.
Study Design: Consensus statement.
Methods: A working group of 4 persons generated a list of statements related to the functional anatomy, indications, donor graft
considerations, surgical treatment, and rehabilitation for the management of large chondral and osteochondral defects in the
patellofemoral joint to form the basis of an initial survey for rating by a group of experts. The Metrics of Osteochondral Allografts
(MOCA) expert group (composed of 28 high-volume cartilage experts) was surveyed on 3 occasions to establish a consensus on the
statements. In addition to assessing agreement for each included statement, experts were invited to propose additional statements
for inclusion or to suggest modifications of existing statements with each round. Predefined criteria were used to refine statement
lists after each survey round. Statements reaching a consensus in round 3 were included within the final consensus document.
Results: A total of 28 experts (100% response rate) completed 3 rounds of surveys. After 3 rounds, 36 statements achieved a
consensus, with over 75% agreement and less than 20% disagreement. A consensus was reached in 100.00% of the statements
relating to functional anatomy of the patellofemoral joint, 88.24% relating to surgical indications, 100.00% relating to surgical
technical aspects, and 100.00% relating to rehabilitation, with an overall consensus of 95.5%.
Conclusion: This study established a strong expert consensus document relating to the functional anatomy, surgical indications,
donor graft considerations for osteochondral allografts, surgical technical aspects, and rehabilitation concepts for the management of large chondral and osteochondral defects in the patellofemoral joint. Further research is required to clinically validate the
established consensus statements and better understand the precise indications for surgery as well as which techniques and graft
processing/preparation methods should be used based on patient- and lesion-specific factors.
Keywords: patellofemoral; cartilage; osteochondral; allograft; consensus; Delphi

Cartilage lesions of the patellofemoral joint are particularly
common; however, surgery is not indicated in many cases,
especially when they are asymptomatic.11,20,26,58 Chondral
and osteochondral injuries of the patellofemoral joint present several challenges for their treatment, as the morphology of the patella and trochlea can have wide variability
between patients. In addition to its unique anatomy, the

patellofemoral joint also experiences very high loads with
daily activities, including 1.3 times the body weight (BW)
during level ambulation, 3.3 times BW during stair ambulation, 5.6 times BW during running, and up to 7.8 times
BW during a deep knee bend or squat.28 Other factors that
add additional complexity include excessive patellar malalignment, maltracking, patella alta or baja, and trochlear
dysplasia, among others.3,4,12,26,32,59
When indicated, multiple surgical options exist for
large symptomatic defects. Matrix-induced autologous
chondrocyte implantation (MACI) and osteochondral
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allograft transplantation (OCA) remain the most commonly utilized methods of treatment. 12,45 These treatments are used routinely in other compartments of the
knee; however, the morphology, alignment, and biomechanics of the patellofemoral joint make some of these techniques particularly challenging. For example, the complex
topography and variable anatomy of the patella and trochlea make OCA technically more demanding than autologous chondrocyte implantation (ACI) because of the need
to match graft morphology to patient anatomy. As a result
of this complexity, inferior outcomes have been reported
with the treatment of symptomatic large patellofemoral
lesions when compared with tibiofemoral cartilage treatments.12,24 In addition, clinical studies, especially clinical
trials, very often focus on the tibiofemoral joint, and the
literature on cartilage restoration in the patellofemoral
joint is much more limited.24,40,80 For those reasons, significant debate remains regarding the indications and
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specifics of each technique for the surgical treatment of
patellofemoral chondral defects.
Despite the growing body of literature on this topic, a
standardized algorithm is lacking, leading to persistent
controversy in the surgical treatment of large symptomatic patellofemoral cartilage injuries. In such instances,
an expert consensus can be synthesized using a modified
Delphi method. This allows for the development of a
group-based consensus. The Delphi method provides several advantages over other group-based processes, including the preservation of participant anonymity that can
reduce the effects of dominant participants.39 Additionally, Delphi consensus statements conducted at a distance
have been demonstrated to be as reliable as face-to-face
panels,93 with further advantages of greater participant
flexibility.42 For the abovementioned reasons, the purpose
of this study was to develop a Delphi consensus statement
on the functional anatomy, indications, donor graft
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TABLE 1
Summary of Results at the End of Each Survey Round in the Delphi Process
Delphi Round
1
2
3

No. of
Responses

Total No. of Statements
Included in Survey

% of Statements Reaching
a Consensus

No. of New
Statements

No. of Modifications
Suggested

35
35
35

35
35
36

69.0
82.0
95.5

0
0
1

0
8
4

considerations, treatment, and rehabilitation for the management of large chondral and osteochondral defects in
the patellofemoral joint.

METHODS
Study Design
A working group of 4 individuals (J.C., B.B.H., A.B.Y., J.F.)
was responsible for facilitating the development of a consensus using modified Delphi techniques as previously
described.14 A comprehensive list of statements was generated under 5 categories: functional anatomy, surgical indications, donor graft considerations for osteochondral
allografts, surgical technical aspects, and rehabilitation
concepts for the management of large chondral and osteochondral defects in the patellofemoral joint. The Metrics of
Osteochondral Allografts (MOCA) expert group was
surveyed on 3 occasions to establish a consensus on the
inclusion/exclusion of each statement.

Identification of Statements
for Inclusion in the First-Round Survey
Potential statements for inclusion in the first-round survey
were prepared by the working group on the basis of recently
published studies, including systematic reviews and metaanalyses of patellofemoral joint cartilage treatment.15,35,69,80
Online surveys were generated to allow respondents to vote
whether statements should be included in an expert consensus document relating to the management of large chondral
and osteochondral defects in the patellofemoral joint. There
were 5 possible responses on a Likert53 scale including
“strongly agree,” “agree,” “neither agree nor disagree,”
“disagree,” or “strongly disagree.” A free-text comment section was included to allow for suggested modifications or
additional statements. The survey was piloted by 3 experts
for face validity, understanding, and acceptability, resulting
in minor modifications.

Establishing Consensus Using Delphi Methods
Delphi methods were used to establish a group consensus
on whether statements should be included in an expert
consensus document relating to the management of large
chondral and osteochondral defects in the patellofemoral
joint.82 A total of 28 experts were included based on their
comprehensive and authoritative knowledge of the topic,
having a known clinical practice that utilizes cartilage

restorative procedures for the patellofemoral joint (minimum of 30 cartilage cases per year), and having frequently
published and/or lectured on the topic (>10 publications on
patellofemoral chondral injuries). Experts were part of a
previously established group (2016) of osteochondral allograft experts (MOCA group).
Experts participated in 3 rounds of surveys between
February and April 2019 (Table 1). First-round surveys
were analyzed, and participants were sent an anonymized
summary of the results together with a second survey. In
round 1, statements were categorized as “essential” and
retained for round 2 if over 70% of respondents agreed and
fewer than 20% disagreed. Statements not meeting these
criteria were discarded or modified according to rater suggestions. The second-round survey also included any new
statements suggested by experts in round 1. In round 2,
participants were asked to rescore the statements and provide free-text comments. In round 2, responses were analyzed, retaining statements if over 70% of respondents
agreed on their inclusion and fewer than 20% disagreed.
Statements retained after round 2 were considered in round
3. Questionnaires were reanalyzed and the cycle repeated in
round 3. For a consensus, defined a priori, statements were
included in the final consensus document if over 75% of
respondents agreed and fewer than 20% disagreed in the
third-round Delphi survey (Table 2 and Figure 1).

DISCUSSION
The most important finding of this study was that a consensus among high-volume experts on the management of
patellofemoral chondral injuries was reached on the majority of the statements (95.5%). Surgical indications were the
most controversial topic with the highest disagreement
reported. Specifically, the Delphi method failed to reach a
consensus for indications for OCA versus ACI. This is most
likely because of the lack of clinical studies comparing the 2
techniques, which results in surgeons’ decisions being
based largely on personal experience. However, overall
strong agreement was reached for all categories including
functional anatomy of the patellofemoral joint, surgical
indications, donor graft considerations for osteochondral
allografts, surgical technical aspects, and rehabilitation
concepts.

Functional Anatomy
The experts felt that the patella and trochlea were both
high-loading (weightbearing) components of the knee. To
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TABLE 2
Levels of Agreement and Disagreement in the Statements Included in the Third-Round Surveya
Section Subheadings and Final Statements
Functional anatomy
The patella and trochlea are both high-loading (weightbearing) components of the knee.55
Surgical indications
Factors that influence the timing and indications for surgery include cause, age, location, concomitant
abnormality, range of motion, and patient expectations.66
OCA and ACI are valid treatments for large focal chondral injuries of the patella.35,37,63,76,88
OCA and ACI are valid treatments for large focal chondral injuries of the trochlea.13,35,63,76,88
Associated significant malalignment and/or maltracking should be addressed with osteotomy
concomitantly or before the cartilage restoration procedure.25,29,35,70,73,76,87,92
Associated patellofemoral instability should be addressed with patellar stabilization procedures
concomitantly or before the cartilage restoration procedure.35,46,81,85,89
Full patellar chondral resurfacing could be indicated in a young patient with subtotal cartilage loss of the
patella.25,35,37,46,88
Uncontained lesions can be treated with OCA.13,37
Uncontained lesions can be treated with ACI as long as the membrane can be fixed to the bone through
sutures/anchors.25,34,35
Bipolar lesions can be treated with OCA for both surfaces.5,16,46,57,64,85
Bipolar lesions can be treated with ACI for both surfaces when there is no significant joint space
narrowing.25,34,35,61,63,76,88
In bipolar patellofemoral lesions, unloading osteotomy should be strongly considered when ACI is
performed.7,35,78
In bipolar patellofemoral lesions, unloading osteotomy should be strongly considered when OCA is
performed.7,78
Relative contraindications for OCA include end-stage osteoarthritis and very restricted range of motion.30
Relative contraindications for ACI include end-stage osteoarthritis and very restricted range of motion.27
OCA is preferred over ACI for patellofemoral conditions that involve uncontained lesions and significant
bone abnormalities such as intralesional osteophytes; revision settings including prior failed
microfracture, prior fracture malunion, significant subchondral bone edema, significant subchondral
cyst formation; and bone loss due to fractures or osteochondritis dissecans fragment
excision.21,31,36,38,60,79,b
ACI can be used in conditions that involve significant bone abnormalities with the “sandwich technique,”
bone grafting, and overlying ACI.62,75
ACI is preferred over OCA in lesions that include the central trochlear groove, the median patellar ridge,
and multifocal lesions.18,35,80,b,c
Donor graft considerations for osteochondral allografts
Fresh osteochondral grafts are preferred over cryopreserved grafts when available.19,47
Presurgical matching should be performed to avoid graft-recipient size mismatching for osteochondral
allografts based on radiography with a sizing marker8,23 and magnetic resonance imaging.8
Surgical technical aspects
Osteochondral allografts should be implanted in <28 days to have adequate chondrocyte viability.2,6,95
The dowel technique is the preferred method for the treatment of focal chondral defects when using
osteochondral allografts.
Ideally, matching areas from the donor graft are preferred.16,37
Preference should be given to matching cartilage surface topography and peripheral step-off over osseous
mismatching.17,43,50,72,83,90
The ideal depth of the allograft should be limited to 6 to 10 mm depending on the size and location of the
graft.91
Attempts should be made to remove all marrow elements utilizing pulse lavage or similar methods.44,58
Impaction of the graft should be avoided when possible, and the graft should be placed in a press-fit
manner when contained.9,71
Supplemental fixation of an osteochondral allograft is needed only if the graft is unstable or full trochlear
and/or patellar resurfacing is performed.10,13,37
When using ACI, one should not exceed the edges of the lesion.41
Suture fixation is not usually required for ACI unless the membrane is unstable after the addition of the
sealant.25,34,35
Rehabilitation
The mean survival rate of patellofemoral osteochondral allografts at 5 and 10 years is higher than 75%.13,37
Patient satisfaction is high, and clinical outcomes are improved in 70% to 80% of patients 10 years after
patellofemoral ACI.63,69,76

% Disagreement % Agreement

0.00

92.86

0.00

100.00

3.57
3.57
0.00

89.29
92.86
96.43

3.57

96.43

0.00

89.29

3.57
0.00

85.71
100.00

3.57
7.14

82.14
85.71

0.00

96.43

3.57

82.14

0.00
0.00
3.57

92.86
96.43
67.86

0.00

85.71

28.57

35.71

0.00
0.00

100.00
92.86

0.00
0.00

96.43
92.86

0.00
0.00

89.29
100.00

0.00

100.00

0.00
0.00

96.43
96.43

0.00

100.00

0.00
0.00

89.29
82.14

0.00
0.00

78.57
89.29
(continued)
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Table 2 (continued)
Section Subheadings and Final Statements

% Disagreement % Agreement

A sequential staged rehabilitation program (range of motion, muscular endurance, strength, and power)
is essential for a successful outcome.65
An early mobilization protocol is safe and should be implemented to avoid arthrofibrosis.13,37,63
Nonweightbearing range of motion is safe and desired if no associated osteotomy is performed.35,54
Progressive weightbearing, as tolerated, with a knee brace locked in full extension does not excessively
load the patellofemoral joint and is safe if no associated osteotomy is performed.35,55,77

0.00

96.43

0.00
7.14
0.00

96.43
89.29
100.00

a

ACI, autologous chondrocyte implantation; OCA, osteochondral allograft transplantation.
Statements not reaching a consensus.
c
Any implantation of cultured chondrocytes in a membrane; this includes all generations and membrane compositions such as Carticel,
matrix-induced autologous chondrocyte implantation, ChondroCelect, Hyalograft C, and NeoCart, among others.
b

this point, Flynn and Soutas-Little28 reported forces of 1.3
times BW during level ambulation, 3.3 times BW during
stair ambulation, 5.6 times BW during running, and up to
7.8 times BW during a deep knee bend or squat. As a significant weightbearing surface, these symptomatic lesions
often require an intervention. However, given the unique
mechanics and morphology, surgical techniques have
greater technical demand when applied to the patellofemoral joint compared with the femoral condyles.

Indications
As loading areas, surgical treatment of symptomatic chondral defects in the patellofemoral joint should be considered
when nonoperative measures fail. While the majority of
experts agreed on most indication statements, 2 statements
did not achieve agreement (indications of ACI vs OCA for
the treatment of certain chondral defects). Several factors
(cause, age, location, concomitant abnormalities, range of
motion, and patient expectations) were considered important when deciding the timing and indications for surgery,
even though the literature is conflicting on how those variables affect outcomes.15 Evidence suggests that age, cause,
and location likely do not affect outcomes, while female sex,
lesions in the patella, large lesions, and bipolar chondral
defects potentially lead to less optimal results.{ Other factors such as concurrent malalignment, maltracking, and
patellar instability should be carefully evaluated during
the workup of patients with chondral lesions, as they were
deemed of utmost importance by the expert panel (they
should be corrected before or at the time of the cartilage
repair procedure). The importance of correcting coexisting
abnormalities and anatomic abnormalities was initially
highlighted by Peterson et al.76 These authors reported
on 224 patients who underwent ACI, recognizing that
patients with patellar lesions had less than optimal outcomes when compared with patients with lesions in the
femoral condyles.11,74 However, when selective tibial tuberosity osteotomy was performed, the improvement in
patients with patellofemoral lesions was similar to that in
patients with lesions in the femoral condyles.76 Several
authors later reported comparable results, acknowledging
{

References 4, 20, 25, 26, 32, 33, 35, 51, 52, 66, 70, 73, 76, 84, 87, 92.

the importance of correcting maltracking before or concurrently with the cartilage procedures.35,46,81,85,89
Both ACI and OCA were considered valid treatments for
large chondral defects in the patella and trochlea except in
cases of end-stage osteoarthritis and/or restricted range of
motion (<100 -110 ). While end-stage arthritis is a contraindication to cartilage repair, subtotal loss or bipolar
lesions without significant joint space narrowing can be
treated with ACI or OCA, especially in young patients.# The
addition of unloading osteotomy can reduce joint surface
pressures up to 30% and is recommended when treating
those patients with bipolar lesions.7,35,78 Even though the
sandwich technique has been described in the treatment of
bone lesions concomitantly with ACI, there was no agreement on its utilization, and OCA was preferred for cases
that include intralesional osteophytes, revision including
prior failed microfracture, prior fracture malunion, significant subchondral stress reactions also known as “bone
edema,” significant subchondral cyst formation, and bone
loss due to fractures or osteochondritis dissecans fragment
excision.21,31,36,38,60,62,75,79
In the patellofemoral joint, morphology matching makes
OCA technically more demanding than ACI. This is
because of the complex topography, with highly variable
shapes of the patella and trochlea. Furthermore, patients
with patellofemoral cartilage lesions often have different
morphology when compared with controls and potential
donors.56 This complicated morphology matching is more
pronounced with the involvement of the central trochlear
groove and median patellar ridge. Still, there was no agreement that ACI is preferred in those situations. With that
being said, while OCA graft matching can be challenging in
the patellofemoral joint, a consensus did not favor ACI in
this setting.

Graft and Surgical Technique Considerations
A consensus was reached in multiple surgical technical
aspects and on donor graft considerations for osteochondral
allografts. When performing OCA, grafts from the same
location are preferred, and matching can be performed by
radiography with a sizing marker or magnetic resonance
#

References 5, 16, 25, 34, 35, 37, 46, 57, 61, 63, 64, 68, 76, 85, 88.
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Figure 1. Stacked leaning bar chart representing the breakdown in agreement levels in the third-round Delphi survey. Bars to the
left of the y-axis indicate disagreement, with bars to the right indicating agreement.

imaging.8,19,23,47 Location matching has been reported to
improve the congruence between the graft and recipient
surfaces.86
Experts agreed that chondrocyte viability is crucial to
graft survival. To this point, the preservation technique
(fresh grafts have greater chondrocyte viability than
cryopreserved grafts), 19,47 timing (implantation in
<28 days),2,6,95 and technique of implantation (avoiding

impaction)9,71 can significantly affect chondrocyte viability.
In this regard, higher impact loads may be encountered
when the graft is thicker than 10 mm and when there is a
>2-mm difference between the graft and recipient hole, and
thus, thinner plugs are now recommended that match the
depth of the socket.71,91 Laboratory studies demonstrated
that high-impact loads adversely affect cell viability, with
less than 50% to 70% of the cells remaining viable in that
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setting.71,91 The load of impact has a larger influence on
chondrocyte death than the number of impacts. Thus, multiple low-load taps are preferred over single high-load taps
if impaction cannot be avoided.94 Therefore, the goal is to
obtain a 6- to 10-mm graft that is flush with the cartilage
surface and in contact with the bottom of the recipient hole,
regardless of subchondral bone matching.** This method
decreases the subsidence of the graft and results in better
restoration of the contact pressure in that compartment.49
Another subject of debate in the 3 rounds of the Delphi
consensus was the treatment of uncontained lesions in the
patellofemoral joint. Experts stated that patellofemoral
chondral injuries can be treated with ACI and OCA with
appropriate modifications to ensure stability. These can be
performed with transosseous sutures or anchors in ACI;
however, MACI might not need any additional fixation if
the uncontained portion is small.25,34,35 In certain situations, OCA might need additional fixation when the graft
is unstable.10,13,37 Headless metal screws or absorbable
internal fixation materials can be used for fixation, with
the acknowledgment that metal screws will need to be
removed once the OCA site has healed.13,37 Other surgical
technical aspects that had agreement were that dowels are
preferred compared with shell grafts when possible15 and
that pulse lavage should be used because it may decrease
the concentration of bone marrow elements.44

Rehabilitation
Last, a sequential, staged rehabilitation program (range of
motion, muscular endurance, strength, and power) was felt
to be essential for a successful outcome among experts.65 In
early phases, a comprehensive patellar and tibiofemoral
mobilization protocol is safe and should be implemented
to avoid arthrofibrosis.13,37,63 Notably, progressive weightbearing as tolerated with a knee brace locked in full extension does not excessively load the patellofemoral joint and is
therefore considered safe if no associated osteotomy is
performed.35,55,77
This expert consensus statement fulfills established criteria for the reporting of Delphi studies22 using a validated
number of experts.1 The 100% response rate across all 3
survey rounds highlights the commitment of these experts
to establish a consensus on the management of patellofemoral chondral injuries. The Delphi technique has additional strengths as well as preserving participants’
anonymity and therefore shields participants from more
influential expert opinions. Furthermore, the potential
influence of any single participant was reduced by including more experts than most published Delphi studies. Last,
the level of agreement required for final inclusion was
higher than most health care Delphi studies22 to ensure
that only statements supported by over 95% of experts were
included. Nevertheless, this study is not without limitations. As with any other consensus statement, although the
statements were created from a review of the literature, the
modifications and suggestions presented are not directly
**References 17, 43, 48, 50, 67, 72, 83, 90, 91.
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derived from data but from expert opinions. Additional
research, including clinical outcomes data, is required to
validate this consensus statement.

CONCLUSION
This study established a strong expert consensus document
relating to the functional anatomy, surgical indications,
donor graft considerations for osteochondral allografts,
surgical technical aspects, and rehabilitation concepts for
the management of large chondral and osteochondral
defects in the patellofemoral joint. Further research is
required to clinically validate the established consensus
statements and better understand the precise indications
for surgery as well as which techniques and graft processing/
preparation methods should be used based on patient- and
lesion-specific factors.
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